email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2644-1373

LOJ Pharmacology & Clinical Research

Research Article(ISSN: 2644-1373)

Genesis, Evaluation and Progression of A Breakthrough Discovery to Efficiently Cure Cancer Through Use of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotics as Adjuvants Along with the Traditional Cancer Therapies, Through Restoration of Healthy and Balanced Intestinal Microbiota and their Microbiome

Volume 1 - Issue 5

Malireddy S Reddy, BVSc (DVM), MS, PhD.*

  • Author Information Open or Close
    • Department of Biopharmacology, International Media and Cultures (IMAC) Inc and ADFAC Labs, Inc., USA

    *Corresponding author: Malireddy S Reddy, Department of Biopharmacology, International Media and Cultures (IMAC) Inc and ADFAC Labs, Inc., 1280 S. Parker Road, Denver, CO 80231, USA.

Received: October 25, 2019;   Published: November 01, 2019

DOI: 10.32474/LOJPCR.2019.01.000121

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


A breakthrough, Multiple Mixed Strain Probiotic Therapy, although originally designed to cure hospital acquired infections, has been discovered serendipitously by Dr. M.S. Reddy to treat cancer with greatest accuracy (60% as opposed to current 20%), with least or no side effects and least or no relapse, when used as an adjuvant therapy along with standard cancer therapies, including immune checkpoint therapy. This discovery can be further refined and improved to treat cancer at 80 to 100% efficacy to save lives of millions of people in the world by significantly improving immune system through positive manipulation of the human gut microbiota and their microbiome. The results of the clinical trials are outlined along with discussion and conclusion. The references listed have been limited to the latest, significant, and directly applicable research discoveries only.

Keywords: Dr MS Reddy’s multiple mixed strain probiotic therapy to treat hospital acquired infections; Nosocomial infections; Dr MS Reddy multiple mixed strain adjuvant cancer therapy; Microbiota; Hospital acquired infections; Immune checkpoint therapy; C Diff; MRSA; Microbiome

Abstract| Introduction| Materials, Methods, and Discussion| Conclusion| Acknowledgment:| References|